New combo targets rare, aggressive CLL complication
NCT ID NCT05388006
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that can develop from chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can help control the disease and improve survival. About 27 adults with this condition will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stanford Cancer Institute Palo Alto
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine
WITHDRAWNSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.